Covid-19 and GI Cancer Management


The safety of upper gastrointestinal cancer patients in the SARS-CoV-2 outbreak is extremely important and most surgeons need to establish a contingency management.The COVID-19 outbreak makes surgical procedures extremely difficult to be performed. The most common criteria to prioritize patients for surgical treatment are stage, tumor biology, presence of tumor-related symptoms, the risk of tumor to become non-resectable, and time interval from neoadjuvant therapy. The multidisciplinary teams can help assigning a priority level to each clinical case.


    Related Conference of Covid-19 and GI Cancer Management

    June 18-19, 2026

    9th International Congress on Viral Hepatitis

    Paris, France
    June 29-30, 2026

    5th International Conference on Gastroenterology and Liver

    Paris, France
    July 06-07, 2026

    9th International Conference on Digestive and Metabolic Diseases

    Amsterdam, Netherlands
    August 03-04, 2026

    21st Euro-Global Gastroenterology Conference

    London, UK
    August 24-25, 2026

    32nd World Conference on Gastroenterology & Hepatology

    Paris, France
    August 25-26, 2026

    18th World Conference on Gynecology, Obstetrics and Women Health

    Barcelona, Spain
    September 07-08, 2026

    26th International Conference on Gastroenterology and Hepatology

    Edinburgh, Scotland
    September 23-24, 2026

    21th European Gastroenterology and Therapeutics Congress

    Barcelona, Spain
    September 29-30, 2026

    7th Global Summit on Earth Science and Climate Change

    Paris, France
    October 19-20, 2026

    25th International Conference on Gastroenterology and Digestive Disorders

    Rome, Italy